Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine-rich repeat and transmembrane domain-containing protein 2 (LRTM2)
- Target
- LRTM2
- Molecular classification
- Transmembrane protein, Leucine-rich repeat (LRR)-containing protein, Other (not a GPCR, receptor, ion channel, enzyme, or transporter)
01
Overview
Leucine-rich repeat and transmembrane domain-containing protein 2 (LRTM2) is a 370-amino acid, type I transmembrane protein conserved in vertebrates. It features a leucine-rich repeat (LRR) domain and is predominantly located in neuronal tissue, especially the olfactory bulb and dorsal striatum. LRTM2 plays a crucial role in protein sorting within striatal projection neurons, affecting the trafficking and localization of inhibitory synaptic components like GAD67 and GABA_B receptor. Knockout models display altered monoamine metabolism, movement abnormalities, and disrupted axonal protein distribution, underscoring its influence on neural circuit physiology. LRTM2 has molecular interactions with heparin and Roundabout receptors but is not classified as a classic therapeutic target or receptor
- Other names
- LRTM2Leucine rich repeat transmembrane protein 2Leucine rich repeats and transmembrane domains 2Leucine-rich repeat and transmembrane domain-containing protein 2
02
Mechanism of action
Not applicable (no drugs known to target LRTM2)
03
Biological functions
Protein sorting in striatal projection neurons, specifically regulating axonal trafficking and localization of inhibitory synaptic proteins GAD67 (glutamate decarboxylase 67) and GABA_B receptor type 1 (GABA_B_R1)Heparin binding and Roundabout receptor (ROBO) binding, suggesting potential regulatory roles in axon guidance or cell signalingInvolved in maintaining proper monoamine dynamics and behavior, including dopamine and serotonin turnover in the striatum
04
Disease associations
Other (no direct link to major diseases established; knockout mice show movement disorders and altered monoamine metabolism, suggesting possible neurological or psychiatric relevance but not established as a human disease biomarker or target)
05
Safety considerations
None known (no therapeutic challenges or safety issues reported, as the protein is not a drug target)
06
Interacting drugs
None known
07
Biomarkers
None established
Beyond the preview
Go deeper on Leucine-rich repeat and transmembrane domain-containing protein 2 (LRTM2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leucine-rich repeat and transmembrane domain-containing protein 2 (LRTM2).